Related Experiment Video
Updated: Aug 3, 2026
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing
M I Furman1, L A Krueger, M D Linden
1Cardiac Catheterization Laboratories, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA 01605, USA. mark.furman@umassmed.edu
Insights
Glycoprotein IIb/IIIa inhibitors like abciximab and eptifibatide significantly reduce soluble CD40 ligand (sCD40L) and leukocyte-platelet aggregate (LPA) formation in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). These agents do not activate platelets at low receptor occupancy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Soluble CD40 ligand (sCD40L) and leukocyte-platelet aggregates (LPA) are elevated in patients experiencing acute coronary syndrome (ACS).
- These biomarkers are implicated in the pathophysiology of ACS and may contribute to adverse cardiovascular events.
Purpose of the Study:
- To evaluate the impact of Glycoprotein IIb/IIIa (GPIIb-IIIa) antagonists, specifically abciximab and eptifibatide, on sCD40L levels and LPA formation.
- To compare these effects against a control group not receiving GPIIb-IIIa antagonists in ACS patients undergoing percutaneous coronary intervention (PCI).
- To assess whether GPIIb-IIIa antagonists activate platelets at low receptor occupancy.
Main Methods:
- A study involving 98 ACS patients undergoing PCI, divided into three groups: abciximab, eptifibatide, and control.
- Soluble CD40 ligand (sCD40L) levels were quantified using enzyme-linked immunosorbent assay (ELISA).
- Leukocyte-platelet aggregate (LPA) formation was measured via whole blood flow cytometry.
Main Results:
- Abciximab and eptifibatide significantly reduced sCD40L levels post-PCI (30% and 11% respectively at end of PCI; 30% and 9% at 18-24h post-PCI).
- Both agents also decreased circulating monocyte-platelet aggregates (MPA), a component of LPA, particularly at 18-24h post-PCI (abciximab: 41%; eptifibatide: 23%).
- Control patients not on clopidogrel showed a trend towards reduced sCD40L and LPA post-PCI, unlike those on clopidogrel.
Conclusions:
- GPIIb-IIIa antagonists effectively reduce circulating sCD40L and inhibit LPA formation in ACS patients undergoing PCI.
- At low receptor occupancy levels, GPIIb-IIIa antagonists do not appear to activate platelets, suggesting a favorable safety profile in this regard.
- The findings support the therapeutic role of GPIIb-IIIa antagonists in managing ACS by modulating key inflammatory and thrombotic markers.
Objective:
To investigate the effects of abciximab, eptifibatide and no GPIIb-IIIa antagonist (control) on soluble CD40 ligand (sCD40L) and the formation of leukocyte-platelet aggregates (LPA) in 98 ACS patients undergoing percutaneous coronary intervention (PCI).
Background:
sCD40L and LPA are increased in patients with ACS.
Methods:
sCD40L was measured by enzyme-linked immunosorbent assay (ELISA) and LPA by whole blood flow cytometry.
Results:
There were no baseline differences between the three groups in sCD40L and LPA. At the end of PCI, sCD40L was unchanged in the controls, decreased by 30% (P < 0.001) in the abciximab group and by 11% (P < 0.02) in the eptifibatide group. Eighteen to 24 h after PCI, sCD40L was unchanged in the controls, reduced 30% (P < 0.001) in the abciximab-treated group and 9% (P < 0.01) in the eptifibatide-treated group. At the end of PCI, circulating monocyte-platelet aggregates (MPA) were reduced by 12% (P = NS) in the abciximab-treated group, 13% in the eptifibatide-treated group (P = NS), but slightly increased in the controls (P = NS). Eighteen to 24 h after PCI, MPA were reduced by 41% (P < 0.001) compared to baseline in the abciximab-treated group, by 23% (P = NS) in the eptifibatide-treated group, and 15% (P = NS) in the controls. In contrast to control patients presenting while on clopidogrel, control patients presenting not on clopidogrel demonstrated a reduction in sCD40L and LPA 18-24 h post-PCI (P = NS). At low receptor occupancy, GPIIb-IIIa antagonists did not augment the release of sCD40L or the number of circulating LPA.
Conclusions:
GPIIb-IIIa antagonists reduce circulating sCD40L and LPA formation in patients with ACS undergoing PCI. At low receptor occupancy, GPIIb-IIIa antagonists do not activate platelets.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:27Peripheral Artery Disease III: Interprofessional Care